Tovetumab (Anti-PDGFRA / CD140a) is a fully humanized IgG2κ monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. It has a potential to be used in research of glioblastoma and non-small cell lung cancer (NSCLC). MW :145 kD.